ClinicalTrials.gg
CompletedNCT00967746Updated Apr 8, 2026

An Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Etonogestrel-releasing Medicated Intrauterine Systems (Study P06060)

A Phase 2 interventional study of Etonogestrel-releasing IUS and Etonogestrel-releasing IUS in Contraception, sponsored by Organon and Co. Completed at 1 site in Germany. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Organon and Co · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

This is a phase 2, randomized, active-controlled, parallel-group, multicenter, single-blind trial of three different doses of etonogestrel releasing medicated intrauterine systems (ENG-MIUS) in healthy parous women in need for contraception.

The primary trial objective is to explore safety and acceptability of three doses of an ENG-releasing medicated intrauterine system (ENG-MIUS) as compared to Multiload-cu 375®.

02

Conditions studied

  • Contraception
03

In context

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female subjects in need for will be selected to participate in the trial;
  • Each subject must be >=18 to \<=40 years of age at screening and in need for contraception;
  • Each subject must have given birth to at least one child (gestational age >=28 weeks);
  • Each subject must have a uterus with a measured length between 6.0 and 9.0 cm (extremes included) from external os to fundus uteri.

Exclusion criteria

Exclusion Criteria:

  • A subject must not be pregnant or suspected to be pregnant;
  • A subject must not have had an ectopic pregnancy in the past or must not have a history or presence of predisposing factors for this condition such as salpingitis, endometritis or pelvic peritonitis;
  • A subject must not have a history or presence of any ;
  • A subject must not have a history or presence of premalignant disease of the uterus or cervix, including endometrial hyperplasia, or (other) sex- sensitive premalignancies;
  • A subject must not have an active venous thromboembolic disorder (e.g. deep vein thrombosis, pulmonary embolism);
  • A subject must not have a history or presence of severe hepatic disease with and/or ALT levels of >=3 times the upper normal limit;
  • A subject must not have congenital or acquired malformations or distortions of the uterus or cervix;
  • A subject must not have large or multiple uterine fibromyomata, or a smaller uterine fibromyoma which may interfere with the insertion of the MIUS/IUD according to the investigator;
  • A subject must not have vaginal bleeding of undiagnosed etiology;
  • A subject must not have dysmenorrhea interfering with daily activities or menorrhagia
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    ENG-MIUS low

    Low dose: ENG-MIUS containing 38 mg ENG with a skin thickness of approximately 350 μm

    Drug: Etonogestrel-releasing IUS

  • Experimental
    ENG-MIUS intermediate

    Intermediate dose: ENG-MIUS containing 61 mg ENG with a skin thickness of approximately 140 μm

    Drug: Etonogestrel-releasing IUS

  • Experimental
    ENG-MIUS high

    High dose: ENG-MIUS containing 72 mg ENG with a skin thickness of approximately 50 μm

    Drug: Etonogestrel-releasing IUS

  • Active comparator
    Multiload

    Multiload-cu 375®

    Device: Multiload-cu 375®

Interventions

  • DrugEtonogestrel-releasing IUS

    Low dose; treatment duration of 6 months with a possible extension to 12 months

    Also known as: SCH 900342, ORG 299001

  • DrugEtonogestrel-releasing IUS

    Intermediate dose; treatment duration of 6 months with a possible extension to 12 months

    Also known as: SCH 900342, ORG 299001

  • DrugEtonogestrel-releasing IUS

    High dose; treatment duration of 6 months with a possible extension to 12 months

    Also known as: SCH 900342, ORG 299001

  • DeviceMultiload-cu 375®

    Duration of 6 months with a possible extension to 12 months

06

What researchers measure

Primary outcomes

  1. The primary efficacy outcome for the trial is insertion and removal characteristics, adverse event reporting and subject's satisfaction with the ENG-MIUS

    Time frame: 6 months

Secondary outcomes

  1. Vaginal bleeding pattern

    Time frame: Days 92 to 182

07

Study locations

1 site
  • Dinox GmbH
    Berlin, D-10115, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Nov 2010 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2009
First posted
Aug 28, 2009
Start
Nov 2009
Primary completionActual
Nov 2010
CompletionActual
Jul 2011
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00967746
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Aug 28, 2009
Start date
Nov 2009
Primary completion
Nov 2010
Completion
Jul 2011
Last update
Apr 8, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion